pCDCAR1 CLD18A2 h(CD3ζ)(CAR-LC199)
The vector of anti-CLD18A2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CLD18A2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CLD18A2 antibody linked to CD3ζ signaling domain. And the vector product was designed for the treatment of pancreatic cancer and gastric cancer.
Details
Targeting Cell Type
T cell
Targeting Diseases
Pancreatic cancer, Gastric cancer
Receptor Construction
scFv-CD3ζ
Discription of Signaling Cassetes
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Target
Synonyms
CLDN18; claudin 18; SFTA5; SFTPJ
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
Carcinoma
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: